Abstracts tagged "Biologics"

Abstract Number: 535 • 2015 ACR/ARHP Annual Meeting
Taurine As a Biomarker for Prediction of Response to Biologic Therapy in Rheumatoid Arthritis
Soshi Takahashi¹, Jun Saegusa², Ikuko Naka¹, Kosaku Tsuda¹, Takaichi Okano¹, Kengo Akashi¹, Miwa Nishida¹, Keisuke Nishimura², Sho Sendo², Yo Ueda¹, Akira Onishi³, Yoshinori Kogata², Goichi Kageyama² and Akio Morinobu², ¹Department of Rheumatology, Kobe University Hospital, Kobe, Japan, ²Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Rheumaology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: To identify a serum biomarker for prediction of the response to biologics (Bio) in patients with rheumatoid arthritis (RA), we performed serum metabolomics analysis…
Abstract Number: 1655 • 2015 ACR/ARHP Annual Meeting
Effectiveness of Monotherapy in Rheumatoid Arthritis (RA) Patients Initiating a Tumor Necrosis Factor Inhibitor (TNFi) Vs a Non-TNFi in a Large US Commercial and Medicare Advantage Plan
Benjamin Chastek¹, Jeffrey R. Curtis², Laura K. Becker³, George J. Joseph⁴ and Chieh-I Chen⁵, ¹Optum Insight, Eden Prairie, MN, ²University of Alabama at Birmingham, Birmingham, AL, ³Optum, Eden Prairie, MN, ⁴Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Monotherapy accounts for approximately 30% of biologic disease-modifying anti-rheumatic drug (DMARD) use in RA (Emery P et al. Ann Rheum Dis 2013;72:1897-904). A validated…
Abstract Number: 2768 • 2015 ACR/ARHP Annual Meeting
Trend and Factors Associated with Switching Treatment after Initial Anti-TNF Therapy Among Patients with Rheumatoid Arthritis
Wenhui Wei¹, Emma Sullivan², Chieh-I Chen³, James Piercy² and Stuart Blackburn², ¹Sanofi-Aventis, Bridgewater, NJ, ²Adelphi Real World, Manchester, United Kingdom, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among rheumatoid arthritis (RA) patients who progress beyond their first biologic disease-modifying antirheumatic drug (bDMARD), in-class cycling between different tumor necrosis factor inhibitors (TNFi)…
Abstract Number: 550 • 2015 ACR/ARHP Annual Meeting
Can Anti-TNF-Induced Autoantibody Conversion be Reversed By Switching to Abatacept Therapy in Patients with RA on Background MTX?
Maya H. Buch¹, A Johnsen², DA Wong² and M Schiff³, ¹University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²Bristol-Myers Squibb, Princeton, NJ, ³University of Colorado, Denver, CO
Background/Purpose: Anti-TNF therapy for RA is associated with antinuclear (ANAs) and anti-double-stranded DNA (anti-dsDNA) autoantibodies.1,2 The effect of biologics on autoantibody-positive patients is unknown. We…
Abstract Number: 1658 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Rheumatoid factor (RF) is considered an important factor in diagnosing rheumatoid arthritis (RA). The association between the treatment efficacy of biological agents and RF…
Abstract Number: 2769 • 2015 ACR/ARHP Annual Meeting
Factors Associated with TNF Switching: a Retrospective Real-World Study of Patients with Rheumatoid Arthritis
Wenhui Wei¹, Keith Knapp², Li Wang³, Chieh-I Chen⁴, Gary Craig², Karen Ferguson² and Sergio Schwartzman⁵, ¹Sanofi-Aventis, Bridgewater, NJ, ²Discus Analytics, Inc., Spokane, WA, ³Director, Analytic Research, STATinMED Research, Plano, TX, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Switching of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patient treatment is common in real-world clinical practice. The context for why patients switch…
Abstract Number: 565 • 2015 ACR/ARHP Annual Meeting
Factors Associated with Sustained Response in Patients with Rheumatoid Arthritis Who Received Rituximab within the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed¹, Chitra Karki², Robert Magner¹, Joel M. Kremer⁴, Ashwini Shewede³ and Jeffrey Greenberg^2,5, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC, Southborough, MA, ³Genentech, Inc., South San Francisco, CA, ⁴Albany Medical College and The Center for Rheumatology, Albany, NY, ⁵NYU School of Medicine, New York, NY
Background/Purpose: The goal of treatment for patients with rheumatoid arthritis (RA) is to achieve and maintain low disease activity (LDA) or remission. Little information is…
Abstract Number: 1672 • 2015 ACR/ARHP Annual Meeting
One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
Tsutomu Takeuchi¹, Hisashi Yamanaka², Masayoshi Harigai³, Ryo Tamamura⁴, Yuchi Kato⁴, Yoshifumi Ukyo⁴, Toshikazu Nakano⁴, Takayuki Ota⁴, Benjamin Hsu⁵ and Yoshiya Tanaka⁶, ¹Keio University School of Medicine, Tokyo, Japan, ²Dept. of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Janssen Pharmaceutical K.K., Tokyo, Japan, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine known for its proinflammatory functions. In rheumatoid arthritis (RA), increased concentrations of IL-6 may stimulate leukocyte recruitment to…
Abstract Number: 2771 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry
Leslie Harrold^1,2, Ani John³, George W. Reed^1,4, Chitra Karki¹, YouFu Li⁴, Joel Kremer⁵, Tmirah Haselkorn⁶ and Jeffrey D. Greenberg^1,7, ¹Corrona, LLC, Southborough, MA, ²Department of Orthopedics and Medicine, University of Massachusetts Medical School, Worcester, MA, ³Genentech, Inc., South San Francisco, CA, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶Genentech, Inc, South San Francisco, CA, ⁷NYU School of Medicine, New York, NY
Background/Purpose: Little is known regarding the real-world use and effectiveness of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) as monotherapy. The effectiveness of TCZ monotherapy…
Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting
Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis
Masao Sato¹ and Masao Takemura², ¹Rheumatology, Matsunami General Hospital, Gifu, Japan, ²Matsunami Reserch Park, Gifu, Japan
Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
Abstract Number: 1675 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Switched CT-P10 from Innovator Rituximab Compared to Those of Maintained CT-P10 in Patients with Rheumatoid Arthritis up to 56 Weeks
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Fidencio Cons Molina⁵, Slawomir Jeka⁶, Jan Brzezicki⁷, Francisco G. Medina-Rodriguez⁸, Pawel Hrycaj⁹, Piotr Wiland¹⁰, Eun Young Lee¹¹, Pavel Shesternya¹², Volodymyr Kovalenko¹³, Leysan Myasoutova¹⁴, Marina Stanislav¹⁵, Sebastiao Radominski¹⁶, Mie Jin Lim¹⁷, Jung-Yoon Choe¹⁸, Sung Young Lee¹⁹ and Sang Joon Lee²⁰, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ⁵Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁶University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁷Wojewodzki Szpital Zespolony w Elablagu, Elblag, Poland, ⁸Rheumatology, LaSalle University, Mexico City, Mexico, ⁹Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ¹²Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹³Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁴City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁵Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ¹⁶CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹⁷Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, ¹⁸Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea, ¹⁹Clinical Planning Department, CELLTRION, Inc., Incheon, South Korea, ²⁰CELLTRION, Inc., Incheon, South Korea
Background/Purpose: Pharmacokinetic (PK) equivalence and similarity of clinical efficacy, safety and immunogenicity up to week 24 were demonstrated between CT-P10, a biosimilar candidate for innovator…
Abstract Number: 2779 • 2015 ACR/ARHP Annual Meeting
Better Drug Survival of Non-TNFi Compared to TNFi Biologics after Non-TNFi Failure in RA Patients: A Single Center Experience
Konstantinos Thomas, Christos Koutsianas, Argyro Lazarini, Christina Tsalapaki, Chrisoula Hatzara, Anna Kandili, Katerina Antonatou and Dimitrios Vassilopoulos, University of Athens Medical School, Clinical Immunology and Rheumatology Unit, 2nd Department of Medicine and Laboratory, Athens, Greece
Background/Purpose: There are sparse data in the literature regarding the drug survival of TNFi vs. non-TNFi biologics in rheumatoid arthritis (RA) patients who have already…
Abstract Number: 586 • 2015 ACR/ARHP Annual Meeting
Titer of Anti-Citrullinated Peptide Antibody Affects the Efficacy of First Biological Treatment in Rheumatoid Arthritis
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Anti-citrullinated protein antibody (ACPA) has been an important marker in diagnosing rheumatoid arthritis (RA). Its predictive value remains unclear; therefore, here we investigated whether…
Abstract Number: 1678 • 2015 ACR/ARHP Annual Meeting
Does the Level of Disease Control Achieved with Biologics Influence Overall Costs for Health Care and Work Loss in RA?
Jonas K Eriksson¹, Martin Neovius², Johan Askling³ and ARTIS study group, ¹Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Numerous studies have modeled whether biologic drugs are good value for money in the treatment of RA, in terms of reducing health care use…
Abstract Number: 2783 • 2015 ACR/ARHP Annual Meeting
What Is the Rate of Primary and Secondary Failure of Anti-TNF in RA Patients? Data from a Rheumatoid Arthritis Cohort
Edward C. Keystone¹, Mohammad Movahedi^2,3, Angela Cesta², Xiuying Li², Sandra Couto², Emmanouil Rampakakis³, John S. Sampalis^3,4, Claire Bombardier^2,5,6 and OBRI Investigators, ¹The Rebecca MacDonald Centre For Arthritis, Mount Sinai Hospital, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³JSS Medical Research, St-Laurent, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Department of Medicine (DOM) and Institute of Health Policy Management, and Evaluation (IHPME), Toronto, ON, Canada, ⁶Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Although the majority of RA patients respond to treatment with anti-TNF agents, some patients present with refractory disease (1ry failure) while others show some…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].